Cargando…
The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy
BACKGROUND: Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression after trastuzumab treatment. METHODS: Dat...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203741/ https://www.ncbi.nlm.nih.gov/pubmed/25330188 http://dx.doi.org/10.1371/journal.pone.0109611 |
_version_ | 1782340424047788032 |
---|---|
author | Gámez-Pozo, Angelo Pérez Carrión, Ramón M. Manso, Luis Crespo, Carmen Mendiola, Cesar López-Vacas, Rocío Berges-Soria, Julia López, Isabel Álvarez Margeli, Mireia Calero, Juan L. Bayo Farre, Xavier González Santaballa, Ana Ciruelos, Eva M. Afonso, Ruth Lao, Juan Catalán, Gustavo Gallego, José V. Álvarez López, José Miramón Bofill, Francisco J. Salvador Borrego, Manuel Ruiz Espinosa, Enrique Vara, Juan A. Fresno Zamora, Pilar |
author_facet | Gámez-Pozo, Angelo Pérez Carrión, Ramón M. Manso, Luis Crespo, Carmen Mendiola, Cesar López-Vacas, Rocío Berges-Soria, Julia López, Isabel Álvarez Margeli, Mireia Calero, Juan L. Bayo Farre, Xavier González Santaballa, Ana Ciruelos, Eva M. Afonso, Ruth Lao, Juan Catalán, Gustavo Gallego, José V. Álvarez López, José Miramón Bofill, Francisco J. Salvador Borrego, Manuel Ruiz Espinosa, Enrique Vara, Juan A. Fresno Zamora, Pilar |
author_sort | Gámez-Pozo, Angelo |
collection | PubMed |
description | BACKGROUND: Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression after trastuzumab treatment. METHODS: Data were collected from women with HER2-positive metastatic breast cancer treated with trastuzumab that experienced a response or stable disease during at least 3 years. Patients having a progression in the first year of therapy with trastuzumab were used as a control. Genes related with trastuzumab resistance were identified and investigated for network and gene functional interrelation. Models predicting poor response to trastuzumab were constructed and evaluated. Finally, a mutational status analysis of selected genes was performed in HER2 positive breast cancer samples. RESULTS: 103 patients were registered in the Long-HER study, of whom 71 had obtained a durable complete response. Median age was 58 years. Metastatic disease was diagnosed after a median of 24.7 months since primary diagnosis. Metastases were present in the liver (25%), lungs (25%), bones (23%) and soft tissues (23%), with 20% of patients having multiple locations of metastases. Median duration of response was 55 months. The molecular analysis included 35 patients from the group with complete response and 18 patients in a control poor-response group. Absence of trastuzumab as part of adjuvant therapy was the only clinical factor associated with long-term survival. Gene ontology analysis demonstrated that PI3K pathway was associated with poor response to trastuzumab-based therapy: tumours in the control group usually had four or five alterations in this pathway, whereas tumours in the Long-HER group had two alterations at most. CONCLUSIONS: Trastuzumab may provide a substantial long-term survival benefit in a selected group of patients. Whole genome expression analysis comparing long-term survivors vs. a control group predicted early progression after trastuzumab-based therapy. Multiple alterations in genes related to the PI3K-mTOR pathway seem to be required to confer resistance to this therapy. |
format | Online Article Text |
id | pubmed-4203741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-42037412014-10-27 The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy Gámez-Pozo, Angelo Pérez Carrión, Ramón M. Manso, Luis Crespo, Carmen Mendiola, Cesar López-Vacas, Rocío Berges-Soria, Julia López, Isabel Álvarez Margeli, Mireia Calero, Juan L. Bayo Farre, Xavier González Santaballa, Ana Ciruelos, Eva M. Afonso, Ruth Lao, Juan Catalán, Gustavo Gallego, José V. Álvarez López, José Miramón Bofill, Francisco J. Salvador Borrego, Manuel Ruiz Espinosa, Enrique Vara, Juan A. Fresno Zamora, Pilar PLoS One Research Article BACKGROUND: Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression after trastuzumab treatment. METHODS: Data were collected from women with HER2-positive metastatic breast cancer treated with trastuzumab that experienced a response or stable disease during at least 3 years. Patients having a progression in the first year of therapy with trastuzumab were used as a control. Genes related with trastuzumab resistance were identified and investigated for network and gene functional interrelation. Models predicting poor response to trastuzumab were constructed and evaluated. Finally, a mutational status analysis of selected genes was performed in HER2 positive breast cancer samples. RESULTS: 103 patients were registered in the Long-HER study, of whom 71 had obtained a durable complete response. Median age was 58 years. Metastatic disease was diagnosed after a median of 24.7 months since primary diagnosis. Metastases were present in the liver (25%), lungs (25%), bones (23%) and soft tissues (23%), with 20% of patients having multiple locations of metastases. Median duration of response was 55 months. The molecular analysis included 35 patients from the group with complete response and 18 patients in a control poor-response group. Absence of trastuzumab as part of adjuvant therapy was the only clinical factor associated with long-term survival. Gene ontology analysis demonstrated that PI3K pathway was associated with poor response to trastuzumab-based therapy: tumours in the control group usually had four or five alterations in this pathway, whereas tumours in the Long-HER group had two alterations at most. CONCLUSIONS: Trastuzumab may provide a substantial long-term survival benefit in a selected group of patients. Whole genome expression analysis comparing long-term survivors vs. a control group predicted early progression after trastuzumab-based therapy. Multiple alterations in genes related to the PI3K-mTOR pathway seem to be required to confer resistance to this therapy. Public Library of Science 2014-10-20 /pmc/articles/PMC4203741/ /pubmed/25330188 http://dx.doi.org/10.1371/journal.pone.0109611 Text en © 2014 Gámez-Pozo et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Gámez-Pozo, Angelo Pérez Carrión, Ramón M. Manso, Luis Crespo, Carmen Mendiola, Cesar López-Vacas, Rocío Berges-Soria, Julia López, Isabel Álvarez Margeli, Mireia Calero, Juan L. Bayo Farre, Xavier González Santaballa, Ana Ciruelos, Eva M. Afonso, Ruth Lao, Juan Catalán, Gustavo Gallego, José V. Álvarez López, José Miramón Bofill, Francisco J. Salvador Borrego, Manuel Ruiz Espinosa, Enrique Vara, Juan A. Fresno Zamora, Pilar The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy |
title | The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy |
title_full | The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy |
title_fullStr | The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy |
title_full_unstemmed | The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy |
title_short | The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy |
title_sort | long-her study: clinical and molecular analysis of patients with her2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203741/ https://www.ncbi.nlm.nih.gov/pubmed/25330188 http://dx.doi.org/10.1371/journal.pone.0109611 |
work_keys_str_mv | AT gamezpozoangelo thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT perezcarrionramonm thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT mansoluis thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT crespocarmen thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT mendiolacesar thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT lopezvacasrocio thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT bergessoriajulia thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT lopezisabelalvarez thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT margelimireia thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT calerojuanlbayo thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT farrexaviergonzalez thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT santaballaana thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT ciruelosevam thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT afonsoruth thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT laojuan thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT catalangustavo thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT gallegojosevalvarez thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT lopezjosemiramon thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT bofillfranciscojsalvador thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT borregomanuelruiz thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT espinosaenrique thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT varajuanafresno thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT zamorapilar thelongherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT gamezpozoangelo longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT perezcarrionramonm longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT mansoluis longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT crespocarmen longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT mendiolacesar longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT lopezvacasrocio longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT bergessoriajulia longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT lopezisabelalvarez longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT margelimireia longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT calerojuanlbayo longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT farrexaviergonzalez longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT santaballaana longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT ciruelosevam longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT afonsoruth longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT laojuan longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT catalangustavo longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT gallegojosevalvarez longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT lopezjosemiramon longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT bofillfranciscojsalvador longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT borregomanuelruiz longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT espinosaenrique longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT varajuanafresno longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy AT zamorapilar longherstudyclinicalandmolecularanalysisofpatientswithher2advancedbreastcancerwhobecomelongtermsurvivorswithtrastuzumabbasedtherapy |